Compare Lowe`s Companies Inc (LOW) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lowe`s Companies Inc vs Sana Biotechnology Inc — how do they compare? Lowe`s Companies Inc trades at $186 (market cap $105.96B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Lowe`s Companies Inc is far larger — about 126.6× Sana Biotechnology Inc's market cap, and Lowe`s Companies Inc pays a 2.65% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Lowe`s Companies Inc for 98 Days and Sana Biotechnology Inc for 23 Days on average.
| LOW | SANA | |
|---|---|---|
Market Cap | $105.96B | $836.71M |
Volume | 4,039,547 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $287.39 | $5.92 |
52-Week Low | $179.50 | $2.68 |
Typical Hold Time | 98 Days | 23 Days |
Enterprise Value | $144.81B | $749.96M |
Dividend Yield | 2.65% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lowe's (LOW) trades at $188.85, up 4.03% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains solid fundamentals with 7.35% net margins and reasonable valuation at 15.96 P/E. Recent drone delivery innovation with DoorDash and Alphabet demonstrates operational adaptation amid challenging home improvement market conditions.
Outlook remains cautious with housing market headwinds, though analyst consensus targets $244.09 (29% upside). Key risks include interest rate sensitivity and competitive pressure from Home Depot. The company's Dividend King status and consistent cash flow generation provide stability for long-term investors.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lowe`s Companies Inc
Lowe's is the second-largest home improvement retailer in the world, operating 1,969 stores and servicing around 230 dealer-owned stores throughout the United States and Canada. The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two thirds of products sold. Lowe's targets retail do-it-yourself (around 75% of sales) and do-it-for-me customers as well as commercial and professional business clients (around 25% of sales). We estimate Lowe's captures a low-double-digit share of the domestic home improvement market, based on U.S. Census data and management's estimates for market size.
Read more on LOW →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
